The U.S. Food and Drug Administration (FDA) issued a final order on April 22, 2026, officially classifying digital therapy devices for amblyopia into Class II. This administrative action, published in the Federal Register, codifies the regulatory framework for a new category of prescription digital therapeutics designed to treat pediatric vision loss through software-based interventions.
The order establishes a new regulation under 21 CFR 886.5500, defining the generic type of device as one that incorporates dichoptic presentations on visual displays through therapeutic algorithms. These devices are intended to treat amblyopia, commonly known as lazy eye, or to improve visual acuity in affected patients. By placing these devices in Class II rather than the default Class III category for novel technologies, the FDA aims to provide a reasonable assurance of safety and effectiveness while reducing the regulatory burden for future manufacturers.
According to the FDA filing, the classification is supported by special controls that manufacturers must meet to market such devices. These controls include rigorous clinical performance testing, software verification and validation, hazard analysis, and specific labeling requirements. The agency noted that these measures are necessary to address risks such as ineffective treatment or potential ocular side effects, ensuring that the digital interventions meet the same standards as traditional ophthalmic treatments.
The decision follows the initial De Novo classification of the first such device, developed by Luminopia, Inc., which was granted in October 2021. While the classification has been applicable since that date, the April 22, 2026, order serves as the final codification of the device type and its associated special controls. This move provides a clear pathway for other developers to seek 510(k) clearance by demonstrating substantial equivalence to the now-established generic category.
Amblyopia affects approximately 3 percent of children and is the leading cause of vision loss in that demographic. Traditional treatments typically involve eye patching or atropine drops, which often face challenges with patient compliance. Digital therapies, such as those covered by this order, allow patients to engage with therapeutic content—often movies or games—through virtual reality headsets or tablets. These systems use dual-action algorithms to modify visual stimuli, encouraging the brain to combine input from both eyes.
The FDA action comes exactly one year after the agency cleared an expanded indication for Luminopia treatment on April 22, 2025, which broadened the eligible patient age range to include children up to 12 years old. The formalization of the Class II status reflects the growing role of prescription digital therapeutics in the U.S. healthcare system. Bradley Cunningham of the FDA Center for Devices and Radiological Health was named as the primary contact for the order.